http://www.unboundmedicine.com/medline/ebm/research/imatinibUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19925926/full_citation/Surgical_management_of_congenital_dermatofibrosarcoma_protuberans_Love WE, Keiler SA, Tamburro JE, et al. 
Surgical management of congenital dermatofibrosarcoma protuberans. [JOURNAL ARTICLE]
J Am Acad Dermatol 2009 Dec; 61(6):1014-1023.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19925597/full_citation/Skin_fragility_and_blistering_with_imatinib_mesylate_Verma S, Murphy G 
Skin fragility and blistering with imatinib mesylate. [JOURNAL ARTICLE]
J Eur Acad Dermatol Venereol 2009 Nov 18.
Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19925053/full_citation/Spectrum_of_BCR_ABL_kinase_domain_mutations_in_patients_with_chronic_myeloid_leukemia_from_India_with_suspected_resistance_to_imatinib_mutations_are_rare_and_have_different_distributions_Markose P, Chendamarai E, Balasubramanian P, et al. 
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. [JOURNAL ARTICLE]
Leuk Lymphoma 2009 Nov 19.
Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19925050/full_citation/Vincristine_but_not_imatinib_could_suppress_mesenchymal_niche's_support_to_lymphoid_leukemic_cells_Fung KL, Liang RH, Chan GC 
Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. [JOURNAL ARTICLE]
Leuk Lymphoma 2009 Nov 19.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19924787/full_citation/Dasatinib_100_mg_once_daily_minimizes_the_occurrence_of_pleural_effusion_in_patients_with_chronic_myeloid_leukemia_in_chronic_phase_and_efficacy_is_unaffected_in_patients_who_develop_pleural_effusion_Porkka K, Khoury HJ, Paquette RL, et al. 
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. [JOURNAL ARTICLE]
Cancer 2009 Nov 18.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19924252/full_citation/Acadesine_Kills_Chronic_Myelogenous_Leukemia__CML__Cells_through_PKC_Dependent_Induction_of_Autophagic_Cell_Death_Robert G, Ben Sahra I, Puissant A, et al. 
Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death. [JOURNAL ARTICLE]
PLoS One 2009; 4(11):e7889.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19924144/full_citation/Cathepsin_B_release_after_imatinib_mediated_lysosomal_membrane_permeabilization_triggers_BCR_ABL_cleavage_and_elimination_of_chronic_myelogenous_leukemia_cells_Puissant A, Colosetti P, Robert G, et al. 
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. [JOURNAL ARTICLE]
Leukemia 2009 Nov 19.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19922893/full_citation/Bioequivalence_of_two_film_coated_tablets_of_imatinib_mesylate_400_mg:_A_randomized_open_label_single_dose_fasting_two_period_two_sequence_crossover_comparison_in_healthy_male_South_American_volunteers_Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et al. 
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. [JOURNAL ARTICLE]
Clin Ther 2009 Oct; 31(10):2224-2232.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19922818/full_citation/Extended_kinase_profile_and_properties_of_the_protein_kinase_inhibitor_Nilotinib_Manley PW, Drueckes P, Fendrich G, et al. 
Extended kinase profile and properties of the protein kinase inhibitor Nilotinib. [JOURNAL ARTICLE]
Biochim Biophys Acta 2009 Nov 13.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19921098/full_citation/Imatinib_mesylate__Glivec__inhibits_Schwann_cell_viability_and_reduces_the_size_of_human_plexiform_neurofibroma_in_a_xenograft_model_Demestre M, Herzberg J, Holtkamp N, et al. 
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. [JOURNAL ARTICLE]
J Neurooncol 2009 Nov 17.
Abstract | Full Citation | Find Related Articles